The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Neuroinflammatory perspectives on the two faces of Alzheimer?s disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777 · cited 1×
“Activated microglial cells, particularly those in the vicinity of neuritic plaques have shown to be immunoreactive for interleukin-1 (Il-1), interleukin-6 (Il-6), and tumour necrosis factor-a (TNF-a) (Griffin et al., 1989; Dickson et al., 1993, Huell et al., 1995).”
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 2×
“Another inflammation-based therapeutic approach for treatment AD is immunization with Ab (Schenk et al., 1999) but this therapeutic option is hampered by severe side effects (Nicoll et al., 2003).”
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 1×
“In addition, these classical NSAIDS have also a direct lowering effect on Ab1–42 production independently of the cyclooxygenase inhibitory effect (Weggen et al., 2001).”
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 1×
“The idea that the neuroinflammatory response is an interesting target for treatment with anti-inflammatory drugs was stimulated by epidemiological studies showing that the use of classical NSAIDs can prevent or retard AD (McGeer et al., 1996; In ‘t Veld et al., 2001).”
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Inflammatory markers and cognition in well-functioning African-American and white elders
Yaffe, K., Lindquist, K., Penninx, B. W., Simonsick, E. M., Pahor, M., Kritchevsky, S., Launer, L., Kuller, L., Rubin, S., & Harris, T. (2003) · Neurology · doi:10.1212/01.wnl.0000073620.42047.d7 · Cited by 706 · cited 2×
“In prospective case-cohort studies it is found that high serum levels of the acute phase proteins ACT, C-reactive protein and Il-6 and low serum levels of insulin-growth factor-1 were each associated with an increased risk of AD (Engelhart, 2002; Schmidt et al., 2002; Dik et al., 2003; Yaffe et al., 2003).”
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
Wyss-Coray, T., Yan, F., Lin, A. H.-T., Lambris, J. D., Alexander, J. J., Quigg, R. J., & Masliah, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162350199 · Cited by 446
The impact of systemic infection on the progression of neurodegenerative disease
Perry, V. H., Newman, T. A., & Cunningham, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1032 · Cited by 428 · cited 1×
“So, the present data suggest that in early stage of AD the increased production can produce clinical symptoms comparable to the sickness behaviour or depression-like state in experimental animal studies or clinical trials with cytokines (Eikelenboom et al., 2002; Perry et al., 2003).”
Cited by
Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265
“colocalized with clusters of activated microglia (18).”
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158
Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice
Zhao, J., Bi, W., Xiao, S., Lan, X., Cheng, X., Zhang, J., Lu, D., Wei, W., Wang, Y., Li, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42286-8 · Cited by 896
A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines
Rubio-Perez, J. M., & Morillas-Ruiz, J. M. (2012) · The Scientific World Journal · doi:10.1100/2012/756357 · Cited by 839
Inflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782
Rivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8304 · Cited by 723
Glycogen synthase kinase-3 signaling in Alzheimer's disease
Lauretti, E., Dincer, O., & Praticò, D. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118664 · Cited by 615
Common mechanisms of amyloid oligomer pathogenesis in degenerative disease
Glabe, C. G. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.04.017 · Cited by 569
“Chronic inflammation may also be a component of the core degenerative pathway as it is frequently observed in neurodegenerative diseases [19, 20 ,45].”
BackgroundIntracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer’s disease
Lester-Coll, N., Rivera, E. J., Soscia, S. J., Doiron, K., Wands, J. R., & de la Monte, S. M. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9102 · Cited by 467
Brain metabolic dysfunction at the core of Alzheimer's disease
de la Monte, S. M., & Tong, M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.012 · Cited by 461
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
M. de la Monte, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 448
Neuroinflammatory processes in Alzheimer’s disease
Heneka, M. T., O’Banion, M. K., Terwel, D., & Kummer, M. P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0438-z · Cited by 433
Particulate Matter in Polluted Air May Increase Biomarkers of Inflammation in Mouse Brain
Campbell, A., Oldham, M., Becaria, A., Bondy, S. C., Meacher, D., Sioutas, C., Misra, C., Mendez, L. B., & Kleinman, M. (2005) · NeuroToxicology · doi:10.1016/j.neuro.2004.08.003 · Cited by 421
Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD.
(2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-27 · Cited by 393
“Repair processes mediated by alternative activation genes, however, can be associated with maintenance of disease and, in particular, enhanced fibrosis [6,12,77].”
Michailidis, M., Moraitou, D., Tata, D. A., Kalinderi, K., Papamitsou, T., & Papaliagkas, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052687 · Cited by 330
de la Monte, S. M., Tong, M., Lester-Coll, N., Plater, Jr., & Wands, J. R. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-10113 · Cited by 325
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Dewachter, I., Walter, J., Klockgether, T., & Van Leuven, F. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-22 · Cited by 309
“Inflammatory changes are observed in AD brain overall, and particularly at the amyloid depots, invariably comprising activated microglia [9,10].”
Neuroglia in neurodegeneration
Heneka, M. T., Rodríguez, J. J., & Verkhratsky, A. (2010) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.11.004 · Cited by 301
de la Monte, S. M. (2012) · Drugs · doi:10.2165/11597760-000000000-00000 · Cited by 265
“Moreover, stresses caused by inhibition of insulin/IGF signalling stimulate AbPP gene expression([76]) and aberrant AbPP cleavage, with attendant increased AbPP-Ab deposition and toxic fibril formation in the brain.([73,77-81]) Persistent oxidative stress leads to constitutive activation of kinases, e.”
BackgroundThe significance of neuroinflammation in understanding Alzheimer’s disease
Eikelenboom, P., Veerhuis, R., Scheper, W., Rozemuller, A. J. M., van Gool, W. A., & Hoozemans, J. J. M. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0575-6 · Cited by 262
Self-citationNeuroinflammation – An Early Event in Both the History and Pathogenesis of Alzheimer’s Disease
Eikelenboom, P., van Exel, E., Hoozemans, J. J. M., Veerhuis, R., Rozemuller, A. J. M., & van Gool, W. A. (2010) · Neurodegenerative Diseases · doi:10.1159/000283480 · Cited by 259
Self-citationLiu, J., Li, H., Gong, T., Chen, W., Mao, S., Kong, Y., Yu, J., & Sun, J. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c02807 · Cited by 199
Marchetti, B., & Abbracchio, M. P. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.08.007 · Cited by 175
Tai, L. M., Ghura, S., Koster, K. P., Liakaite, V., Maienschein‐Cline, M., Kanabar, P., Collins, N., Ben‐Aissa, M., Lei, A. Z., Bahroos, N., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13072 · Cited by 165
Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain
Korolainen, M. A., Auriola, S., Nyman, T. A., Alafuzoff, I., & Pirttilä, T. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.05.021 · Cited by 133
Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging
Zimmer, E. R., Leuzy, A., Benedet, A. L., Breitner, J., Gauthier, S., & Rosa-Neto, P. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-120 · Cited by 121
“elevated in AD patients [8,9].”
Complement activation in very early Alzheimer disease
Zanjani, H., Finch, C. E., Kemper, C., Atkinson, J., McKeel, D., Morris, J. C., & Price, J. L. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000165506.60370.94 · Cited by 115
Innate immune system and inflammation in Alzheimer’s disease: From pathogenesis to treatment
Serpente, M., Bonsi, R., Scarpini, E., & Galimberti, D. (2014) · Neuroimmunomodulation · doi:10.1159/000356529 · Cited by 87
Neural ageing and synaptic plasticity: prioritizing brain health in healthy longevity
Navakkode, S., & Kennedy, B. K. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1428244 · Cited by 75
The α-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease
McGeer, P. L., & McGeer, E. G. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.04.008 · Cited by 41
Current knowledge of chromosome 12 susceptibility genes for late-onset Alzheimer's disease
D’Introno, A., Solfrizzi, V., Colacicco, A. M., Capurso, C., Amodio, M., Todarello, O., Capurso, A., Kehoe, P. G., & Panza, F. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.020 · Cited by 23
Bai, Q., & Zhao, Z. (2022) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2147 · Cited by 12
Metadata
- Authors
- Eikelenboom, P., & van Gool, W. A.
- Venue
- Journal of Neural Transmission
- Published
- 2004-03-01
- Volume
- 111
- Issue
- 3
- Pages
- 281-294
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W1998849703
- Cited by
- 182
- References
- 14
- FWCI
- 10.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.